ClinicalTrials.gg
Active, not recruitingNCT06616532Updated Oct 22, 2026

PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer

A Phase 3 interventional study of PM8002 and Paclitaxel in SCLC, sponsored by Biotheus Inc.. Active, not recruiting at 45 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Biotheus Inc. (part of BioNTech SE) · Phase 3, Interventional, and Treatment

Updated Oct 22, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
404
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with Paclitaxel as second-line treatment for SCLC

Read the detailed description

This multicenter, randomized, open-label phase III study will evaluate the efficacy and safety of PM8002 in combination with Paclitaxel versus Investigator's Choice (Topotecan or Paclitaxel) as second-line treatment for subjects with SCLC.

02

Conditions studied

  • SCLC

Keywords

  • Second-line
03

In context

Lead sponsor

Biotheus Inc. is the lead sponsor of 18 studies on the registry; 8 are open to participants now.

First submitted before Biotheus Inc. became part of BioNTech SE.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary participation in this clinical study; full understanding of the study and voluntary signing the form; willing to follow and abling to complete all trial procedures;
  2. Age ≥18 years but ≤75 years;
  3. or cytologically confirmed SCLC;
  4. Advanced SCLC that has progressed or replased after platinum-containing chemotherapy (extensive-stage patients must have received );
  5. Having adequate organ functions;
  6. The Eastern Cancer Cooperative Group () performance score of 0 or 1;
  7. of 12 weeks or more;
  8. Having at least one measurable tumor lesion according to v1.1;

Exclusion criteria

Exclusion Criteria:

  1. History of severe allergic disease, severe drug allergy or have known allergy to any component of the study drugs;
  2. Previous treatment with Paclitaxel or Topotecan or anti-vascular endothelial growth factor (VEGF) target drugs;
  3. Current presence of severe superior vena cava syndrome and spinal cord compression;
  4. Adverse events resulting from prior anti-tumor therapies should be assessed and graded according to the 5.0 criteria, subjects whose AEs have not returned to Grade 1 or below;
  5. Evidence of significant clotting disorder or other significant bleeding risk;
  6. History of severe, uncontrollable, or active cardiovascular diseases within 6 months;
  7. Current presence of uncontrollable pleural, pericardial, and peritoneal effusions;
  8. (HIV) infection or known acquired immunodeficiency syndrome;
  9. History of hematopoietic stem cell transplantation or allogeneic organ transplantation;
  10. History of alcohol abuse, psychotropic substance abuse or drug abuse;
  11. Pregnant or lactating women;
  12. Other conditions considered unsuitable for this study by the investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
404 participants (estimated)

Study arms

  • Experimental
    PM8002+Paclitaxel

    Subjects will be administered with PM8002 in combination with Paclitaxel via intravenously (IV) infusion.

    Drug: PM8002 · Drug: Paclitaxel

  • Active comparator
    Chemotherapy

    Subjects will be administered with Investigator's Choice(Topotecan or Paclitaxel) via intravenously (IV) infusion Q3W.

    Drug: Paclitaxel · Drug: Topotecan

Interventions

  • DrugPM8002

    Following a predefined dose and date.

  • 175mg/m2 via IV infusion on Day 1 Q3W

  • 1.25mg/m2/day via IV infusion on Days 1-5 Q3W

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    Overall survival is defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis are censored at the date of the last follow-up.

    Time frame: Up to approximately 32 months from first patient in

Secondary outcomes

  1. Progression-Free Survival (PFS) assessed by evaluated by investigator

    PFS is defined as the time from randomization to the first documented PD per RECIST 1.1 based on assessments by investigator or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD.

    Time frame: Up to approximately 32 months from first patient in

  2. Objective response rate (ORR) evaluated by investigator

    ORR is defined as the percentage of participants in the analysis population who have a complete response (CR: disappearance of all lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions). The percentage of participants who experienced a CR or PR as assessed by investigators based on RECIST 1.1 is presented.

    Time frame: Up to approximately 32 months from first patient in

  3. Disease control rate (DCR)

    DCR is defined as the sum rate of CR, PR and Stable Disease (SD), as determined by investigators based on RECIST v1.1

    Time frame: Up to approximately 32 months from first patient in

  4. Time to response (TTR)

    Time to response(TTR) is defined as the time from randomization to the first documented PR or CR assssed by investigator based on RECIST v1.1

    Time frame: Up to approximately 32 months from first patient in

  5. Duration of response (DOR)

    DoR is defined as the time period from the date of initial CR or PR until the date of PD or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 32 months from first patient in

  6. 6 month PFS rate

    PFS rate corresponding to the 6th month of the progression-free survival curve

    Time frame: Up to approximately 32 months from first patient in

  7. 12 month PFS rate

    PFS rate corresponding to the 12th month of the progression-free survival curve

    Time frame: Up to approximately 32 months from first patient in

  8. 12 month OS rate

    OS rate corresponding to the 12th month of the overall survival curve

    Time frame: Up to approximately 32 months from first patient in

  9. Incidence and severity of Adverse Event (AE) according to CTCAE 5.0

    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment.

    Time frame: Up to 30 days after last treatment

  10. Anti-drug antibody (ADA)

    To evaluate the incidence and characteristics of ADA to PM8002

    Time frame: Up to 30 days after last treatment

  11. Health related quality of life (HRQoL)

    Differences in the scores of health-related quality of life (HRQol)

    Time frame: Up to 30 days after last treatment

07

Study locations

45 sites
08

References and documents

Individual participant data

Plan to share: Yes — The data will be published or presented for publications (poster, abstract,articles or papers) or any presentations.

Time frame: After the trial completed.

Access criteria: NCI is committed to sharing data in accordance with NIH policy.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2024 (actual). Primary completion is estimated for May 2027, 30 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: Jan 2027 → May 2027, on Oct 22, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2024
First posted
Sep 27, 2024
StartActual
Nov 13, 2024
Primary completionEst.
May 2027was Jan 2027
CompletionEst.
Dec 2028
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 25, 2027→May 2027
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Primary completion Jan 25, 2027→May 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06616532
Lead sponsor
Biotheus Inc.
Responsible party
Sponsor
First posted
Sep 27, 2024
Start date
Nov 13, 2024
Primary completion
May 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 22, 2026

Study contacts

Caicun Zhou
principal investigator · Shanghai East Hospital
Haifeng Liu
principal investigator · Jilin Provincial Tumor Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pumitamig

Start the discussion